NeuroPace, Inc. (NPCE) AI Stock Analysis

NeuroPace, Inc. is a medical device company focused on treatments for medically refractory focal epilepsy. Its primary offering is the RNS system (Responsive Neurostimulation system), which delivers personalized neuromodulation therapy directly at the seizure source based on real-time needs. The system continuously records brain activity data to help clinicians monitor patients in person and remotely. NeuroPace works with hospital facilities for initial implantations and subsequent replacement procedures. Founded in 1997 and based in Mountain View, California, the company is also working to expand RNS applications to address a broader range of neurological disorders.

Annual revenue grew from $45.2M in FY2021 to $100.0M in FY2025, representing a 5-year revenue CAGR of 19.4%. Gross margin improved from 74.0% in FY2021 to 77.2% in FY2025. Over the same period, operating margin narrowed from -52.5% to -16.3%, and net loss narrowed from -$36.1M to -$21.5M. In the latest quarter ended June 30, 2026, quarterly revenue grew 17.1% year-over-year. For the trailing twelve months, revenue reached $107.0M, operating margin was -22.5%, and EPS was -$0.57.

As of June 30, 2026, NeuroPace held $51.7M in cash and short-term investments against total debt of $69.9M, resulting in net debt of $18.2M. The company had a current ratio of 4.94 and a debt-to-equity ratio of 5.88 on shareholders' equity of $11.9M. In FY2025, operating cash flow was -$11.0M and free cash flow was -$11.3M. Capital expenditures were $332,000, while share buybacks totaled $49.5M.

NeuroPace trades at a market capitalization of $420.1M and an enterprise value of $507.4M. Its price-to-sales ratio is 3.9x, compared to 4.1x for the median of its US-listed Healthcare peers. The company has a forward P/E of 158.7x, above the peer group median of 17.3x, and an EV-to-revenue multiple of 4.7x. Over the past year, the stock returned 15.0%, trailing the S&P 500 (SPY) return of 16.8%.

Wall Street coverage includes 9 Strong Buy ratings and 1 Buy rating. The mean price target is $20.00, which is 63.4% above the last close of $12.24. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $100.3M and an EPS of -$0.43. For the following fiscal year, 9 analysts project revenue of $122.4M and EPS of -$0.22. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of NeuroPace, Inc. (NPCE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NPCE income statement, NPCE balance sheet, NPCE key metrics, NPCE analyst forecast, NPCE chart. See the NPCE stock overview for the latest quote and news.